1st Quarter - Report

INTERNATIONAL MYELOMA FOUNDATION for INTERNATIONAL MYELOMA FOUNDATION

Firm
Client
Income
—
Expenses
$49,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act

LobbyistCovered position, as disclosed
ARIN ASSERO —
MEGHAN BUZBY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2746 (112th), S. 296 (112th), H.R. 2245 (112th)

Medical/Disease Research/Clinical Labs MED

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act

LobbyistCovered position, as disclosed
ARIN ASSERO —
MEGHAN BUZBY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 296 (112th), H.R. 2245 (112th), H.R. 2746 (112th)

Budget/Appropriations BUD

No Bill Number, Labor HHS & Education, FY 2013 No Bill Number, Agriculture, FY 2013

LobbyistCovered position, as disclosed
ARIN ASSERO —
MEGHAN BUZBY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.